Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy chinese men: A phase I, randomized, open-label, single- and multiple-dose study

Clinical Therapeutics

Volumn 30, Issue 7, 2008, Pages 1290-1299

  Jiang, Juanjuan ^a   Tian, Lei ^a   Huang, Yiling ^a   Li, Yishi ^a   Xu, Li ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

active metabolite; aranidipine; pharmacodynamics; pharmacokinetics

Indexed keywords

ARANIDIPINE; DRUG METABOLITE; M 1; METHYL 2 HYDROXOPROPYL 1,4 DIHYDRO 2,6 DIMETHYL 4 (2 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLATE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; BODY HEIGHT; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; HEADACHE; HEART PALPITATION; HEART RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; SUSTAINED DRUG RELEASE; TANDEM MASS SPECTROMETRY; VITAL SIGN;

ADULT; CALCIUM CHANNEL BLOCKERS; DELAYED-ACTION PREPARATIONS; DIHYDROPYRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MIDDLE AGED; TABLETS, ENTERIC-COATED;

EID: 48549101215     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(08)80053-7     Document Type: Article

References (15)

1. Epstein B.J., Vogel K., and Palmer B.F. Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs 67 (2007) 1309-1327
2. Weber M.A. Calcium channel antagonists in the treatment of hypertension. Am J Cardiovasc Drugs 2 (2002) 415-431
3. Grossman E., and Messerli F.H. Calcium antagonists. Prog Cardiovasc Dis 47 (2004) 34-57
4. Van Zwieten P.A., and Pfaffendorf M. Similarities and differences between calcium antagonists: Pharmacological aspects. J Hypertens Suppl 11 (1993) S3-S11
5. Struyker-Boudier H.A., Smits J.F., and De Mey J.G. The pharmacology of calcium antagonists: A review. J Cardiovasc Pharmacol 15 Suppl 4 (1990) S1-S10
6. Leonetti G. The effects of calcium antagonists on electrolytes and water balance in hypertensive patients. J Cardiovasc Pharmacol 24 SupplA (1994) S25-S29
7. Ohashi K., and Ebihara A. Aranidipine (MPC-1304): A new dihydropyridine calcium antagonist: A review of its antihypertensive action. Cardiovasc Drug Rev 14 (1996) 1-16
8. Ichihara K., Okumura K., Kamei H., et al. Renal effects of the calcium channel blocker aranidipine and its active metabolite in anesthetized dogs and conscious spontaneously hypertensive rats. J Cardiovasc Pharmacol 31 (1998) 277-285
9. Miyoshi K., Miyake H., Ichihara K., et al. Contribution of aranidipine metabolites with slow binding kinetics to the vasodilating activity of aranidipine. Naunyn Schmiedebergs Arch Pharmacol 355 (1997) 119-125
10. Shimosawa T., Ando K., and Takahashi K. Effect of aranidipine, a long-acting Ca antagonist, on circadian variation of blood pressure in essential hypertension patients [in Japanese]. J Clin Ther Med 17 (2001) 1307-1313
11. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. As amended by the 52nd WMA General Assembly; Edinburgh, Scotland; October 2000.
12. European Medicines Agency. ICH Topic E 6 (R1). Guideline for Good Clinical Practice [EMEA Web Site].
13. (May 28, 2008). http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf Accessed
14. Tian L., Jiang J., Huang Y., et al. Determination of aranidipine and its active metabolite in human plasma by liquid chromatography/negative electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 20 (2006) 2871-2877
15. Smith B.P., Vandenhende F.R., De-Sante K.A., et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res 17 (2000) 1278-1283